{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:00:29Z","timestamp":1787313629014,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T00:00:00Z","timestamp":1710979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T00:00:00Z","timestamp":1710979200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>As the population of people with HIV ages, concerns over managing age-related comorbidities, polypharmacy, immune recovery, and drug-drug interactions while maintaining viral suppression have arisen. We present pooled TANGO and SALSA efficacy and safety results dichotomized by age (&lt;\u200950 and\u2009\u2265\u200950\u00a0years).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Week 48 data from the open-label phase 3 TANGO and SALSA trials evaluating switch to once-daily dolutegravir\/lamivudine (DTG\/3TC) fixed-dose combination vs continuing current antiretroviral regimen (CAR) were pooled. Proportions of participants with HIV-1 RNA\u2009\u2265\u200950 and\u2009&lt;\u200950 copies\/mL (Snapshot, intention-to-treat exposed) and safety were analyzed by age category. Adjusted mean change from baseline in CD4\u2009+\u2009cell count was assessed using mixed-models repeated-measures analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 1234 participants, 80% of whom were male, 29% were aged\u2009\u2265\u200950\u00a0years. Among those aged\u2009\u2265\u200950\u00a0years, 1\/177 (&lt;\u20091%) DTG\/3TC participant and 3\/187 (2%) CAR participants had HIV-1 RNA\u2009\u2265\u200950 copies\/mL at 48\u00a0weeks; proportions with HIV-1 RNA\u2009&lt;\u200950 copies\/mL were high in both treatment groups (\u2265\u200992%), consistent with overall efficacy and similar to observations in participants aged\u2009&lt;\u200950\u00a0years (\u2265\u200993%). Regardless of age category, CD4\u2009+\u2009cell count increased or was maintained from baseline with DTG\/3TC. Change from baseline in CD4\u2009+\u2009\/CD8\u2009+\u2009ratio was similar across age groups and between treatment groups. One CAR participant aged\u2009&lt;\u200950\u00a0years had confirmed virologic withdrawal, but no resistance was detected. In the DTG\/3TC group, incidence of adverse events (AEs) was similar across age groups. Proportions of AEs leading to withdrawal were low and comparable between age groups. Although drug-related AEs were generally low, across age groups, drug-related AEs were more frequent in participants who switched to DTG\/3TC compared with those who continued CAR. While few serious AEs were observed in both treatment groups, more were reported in participants aged\u2009\u2265\u200950\u00a0years vs\u2009&lt;\u200950\u00a0years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Among individuals with HIV-1, switching to DTG\/3TC maintained high rates of virologic suppression and demonstrated a favorable safety profile, including in those aged\u2009\u2265\u200950\u00a0years despite higher prevalence of concomitant medication use and comorbidities.<\/jats:p>\n                    <jats:p>\n                      <jats:italic>Trial registration number:<\/jats:italic>\n                      TANGO, NCT03446573 (February 27, 2018); SALSA, NCT04021290 (July 16, 2019).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12981-024-00604-9","type":"journal-article","created":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T10:02:57Z","timestamp":1711015377000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Efficacy and safety of switching to dolutegravir\/lamivudine in virologically suppressed people with HIV-1 aged\u2009\u2265\u200950 years: week 48 pooled results from the TANGO and SALSA studies"],"prefix":"10.1186","volume":"21","clinical-trial-number":[{"clinical-trial-number":"nct03446573","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04021290","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Sharon","family":"Walmsley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don E.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"G\u00f3rgolas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro E.","family":"Cahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Lutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Lacombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Princy N.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Wynne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Grove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilda","family":"Bontempo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riya","family":"Moodley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinyere","family":"Okoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Kisare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryn","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mounir","family":"Ait-Khaled","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,21]]},"reference":[{"issue":"6","key":"604_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-047870","volume":"11","author":"NP Sematlane","year":"2021","unstructured":"Sematlane NP, Knight L, Masquillier C, Wouters E. Adapting to, integrating and self-managing HIV as a chronic illness: a scoping review protocol. BMJ Open. 2021;11(6): e047870.","journal-title":"BMJ Open"},{"key":"604_CR2","unstructured":"UNAIDS. The gap report 2014: people aged 50 years and older. 2014. https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/12_Peopleaged50yearsandolder.pdf. Accessed on 23 Jun 2023."},{"issue":"11","key":"604_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0207005","volume":"13","author":"CS Autenrieth","year":"2018","unstructured":"Autenrieth CS, Beck EJ, Stelzle D, Mallouris C, Mahy M, Ghys P. Global and regional trends of people living with HIV aged 50 and over: estimates and projections for 2000\u20132020. PLoS ONE. 2018;13(11): e0207005.","journal-title":"PLoS ONE"},{"issue":"3","key":"604_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-7568(22)00041-1","volume":"3","author":"The Lancet Healthy Longevity","year":"2022","unstructured":"The Lancet Healthy Longevity. Ageing with HIV. Lancet Healthy Longev. 2022;3(3): e119.","journal-title":"Ageing with HIV. Lancet Healthy Longev"},{"key":"604_CR5","unstructured":"UNAIDS. The path that ends AIDS: UNAIDS Global AIDS Update 2023. 2023. https:\/\/www.unaids.org\/en\/resources\/documents\/2023\/global-aids-update-2023. Accessed 6 Feb 2024."},{"key":"604_CR6","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ijid.2016.10.004","volume":"53","author":"EJ Wing","year":"2016","unstructured":"Wing EJ. HIV and aging. Int J Infect Dis. 2016;53:61\u20138.","journal-title":"Int J Infect Dis"},{"issue":"1","key":"604_CR7","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1001\/jama.2022.22246","volume":"329","author":"RT Gandhi","year":"2023","unstructured":"Gandhi RT, Bedimo R, Hoy JF, Landovitz RJ, Smith DM, Eaton EF, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society-USA Panel. JAMA. 2023;329(1):63\u201384.","journal-title":"JAMA"},{"issue":"7","key":"604_CR8","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/S1473-3099(15)00056-0","volume":"15","author":"M Smit","year":"2015","unstructured":"Smit M, Brinkman K, Geerlings S, Smit C, Thyagarajan K, van Sighem A, et al. Future challenges for clinical care of an ageing population infected with HIV: a modelling study. Lancet Infect Dis. 2015;15(7):810\u20138.","journal-title":"Lancet Infect Dis"},{"issue":"Suppl 4","key":"604_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25986","volume":"25","author":"L Marty","year":"2022","unstructured":"Marty L, Diawara Y, Rachas A, Grabar S, Costagliola D, Supervie V. Projection of age of individuals living with HIV and time since ART initiation in 2030: estimates for France. J Int AIDS Soc. 2022;25(Suppl 4): e25986.","journal-title":"J Int AIDS Soc"},{"key":"604_CR10","unstructured":"National Institute on Aging. HIV, AIDS, and older adults. 2021. https:\/\/www.nia.nih.gov\/health\/hiv-aids-and-older-adults. Accessed 17 Jan 2023."},{"issue":"1","key":"604_CR11","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1089\/aid.2014.0205","volume":"31","author":"RE Johnston","year":"2015","unstructured":"Johnston RE, Heitzeg MM. Sex, age, race and intervention type in clinical studies of HIV cure: a systematic review. AIDS Res Hum Retroviruses. 2015;31(1):85\u201397.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"2","key":"604_CR12","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1080\/25787489.2021.1941672","volume":"22","author":"F Spinelli","year":"2021","unstructured":"Spinelli F, Prakash M, Slater J, van der Kolk M, Bassani N, Grove R, et al. Dolutegravir-based regimens in treatment-naive and treatment-experienced aging populations: analyses of 6 phase III clinical trials. HIV Res Clin Pract. 2021;22(2):46\u201354.","journal-title":"HIV Res Clin Pract"},{"issue":"3","key":"604_CR13","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.2105\/AJPH.2012.301161","volume":"103","author":"S Cahill","year":"2013","unstructured":"Cahill S, Valad\u00e9z R. Growing older with HIV\/AIDS: new public health challenges. Am J Public Health. 2013;103(3): e7\u201315.","journal-title":"Am J Public Health"},{"issue":"9","key":"604_CR14","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1177\/0956462416679550","volume":"28","author":"U Naumann","year":"2017","unstructured":"Naumann U, Moll A, Schleehauf D, Lutz T, Schmidt W, Jaeger H, et al. Similar efficacy and tolerability of raltegravir-based antiretroviral therapy in HIV-infected patients, irrespective of age group, burden of comorbidities and concomitant medication: real-life analysis of the German \u201cWIP\u201d cohort. Int J STD AIDS. 2017;28(9):893\u2013901.","journal-title":"Int J STD AIDS"},{"issue":"2","key":"604_CR15","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1177\/0956462420942020","volume":"32","author":"B Funke","year":"2021","unstructured":"Funke B, Spinner CD, Wolf E, Heiken H, Christensen S, Stellbrink HJ, et al. High prevalence of comorbidities and use of concomitant medication in treated people living with HIV in Germany\u2014results of the BESIDE study. Int J STD AIDS. 2021;32(2):152\u201361.","journal-title":"Int J STD AIDS"},{"issue":"11","key":"604_CR16","doi-asserted-by":"publisher","first-page":"4432","DOI":"10.1111\/bcp.14869","volume":"87","author":"A Calcagno","year":"2021","unstructured":"Calcagno A, de Nicol\u00f2 A, Pizzi C, Trunfio M, Tettoni C, Ferrara M, et al. Medication burden and clustering in people living with HIV undergoing therapeutic drug monitoring. Br J Clin Pharmacol. 2021;87(11):4432\u20138.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"604_CR17","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1089\/apc.2015.0199","volume":"30","author":"HB Krentz","year":"2016","unstructured":"Krentz HB, Gill MJ. The impact of non-antiretroviral polypharmacy on the continuity of antiretroviral therapy (ART) among HIV patients. AIDS Patient Care STDS. 2016;30(1):11\u20137.","journal-title":"AIDS Patient Care STDS"},{"key":"604_CR18","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2147\/PPA.S340621","volume":"16","author":"C Zheng","year":"2022","unstructured":"Zheng C, Meng J, Xiao X, Xie Y, Zhao D, Wang H. Polypharmacy, medication-related burden and antiretroviral therapy adherence in people living with HIV aged 50 and above: a cross-sectional study in Hunan, China. Patient Prefer Adherence. 2022;16:41\u20139.","journal-title":"Patient Prefer Adherence"},{"issue":"8","key":"604_CR19","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1111\/hiv.13122","volume":"22","author":"MM Murray","year":"2021","unstructured":"Murray MM, Lin J, Buros Stein A, Wilcox ML, Cottreau J, Postelnick M, et al. Relationship of polypharmacy to HIV RNA suppression in people aged \u2265 50 years living with HIV. HIV Med. 2021;22(8):742\u20139.","journal-title":"HIV Med"},{"issue":"6","key":"604_CR20","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1093\/cid\/ciac036","volume":"75","author":"O Osiyemi","year":"2022","unstructured":"Osiyemi O, De Wit S, Ajana F, Bisshop F, Portilla J, Routy JP, et al. Efficacy and safety of switching to dolutegravir\/lamivudine versus continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: results through week 144 from the phase 3, noninferiority TANGO randomized trial. Clin Infect Dis. 2022;75(6):975\u201386.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"604_CR21","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1093\/cid\/ciac130","volume":"76","author":"JM Llibre","year":"2023","unstructured":"Llibre JM, Brites C, Cheng C-Y, Osiyemi O, Galera C, Hocqueloux L, et al. Efficacy and safety of switching to the 2-drug regimen dolutegravir\/lamivudine versus continuing a 3- or 4-drug regimen for maintaining virologic suppression in adults living with human immunodeficiency virus 1 (HIV-1): week 48 results from the phase 3, noninferiority SALSA randomized trial. Clin Infect Dis. 2023;76(4):720\u20139.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"604_CR22","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/QAD.0000000000003070","volume":"36","author":"P Cahn","year":"2022","unstructured":"Cahn P, Sierra Madero J, Arribas JR, Antinori A, Ortiz R, Clarke AE, et al. Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy\u2013naive adults with HIV-1 infection. AIDS. 2022;36(1):39\u201348.","journal-title":"AIDS"},{"key":"604_CR23","unstructured":"Ait-Khaled M, Nascimento M-C, Pappa KA, Wang R, Wright J, Tenorio AR, et al. Switching to DTG\/3TC fixed-dose combination (FDC) is non-inferior to continuing a TAF-based regimen through 48 weeks: subgroup analyses from the TANGO study. Presented at: 17th European AIDS Conference; November 6\u20139, 2019; Basel, Switzerland."},{"key":"604_CR24","unstructured":"Taylor S, Andrade-Villanueva JF, Kaplan R, Nahass R, Hocqueloux L, Scholten S, et al. Switching to DTG\/3TC is non-inferior to continuing current antiretroviral regimen at week 48: SALSA subgroup analyses. Presented at: 18th European AIDS Conference; October 27\u201330, 2021; London, UK."},{"key":"604_CR25","unstructured":"Karabon P. Rare events or non-convergence with a binary outcome? The power of Firth regression in PROC LOGISTIC. Presented at: SAS\u00ae Global Forum 2020; June 16, 2020; Virtual."},{"key":"604_CR26","unstructured":"Dovato [prescribing information]. Durham, NC: ViiV Healthcare; 2023."},{"issue":"Suppl 2","key":"604_CR27","doi-asserted-by":"publisher","first-page":"S189","DOI":"10.1097\/QAD.0000000000003083","volume":"35","author":"S Shah","year":"2021","unstructured":"Shah S, Pilkington V, Hill A. Is tenofovir disoproxil fumarate associated with weight loss? AIDS. 2021;35(Suppl 2):S189\u201395.","journal-title":"AIDS"},{"issue":"8","key":"604_CR28","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1093\/cid\/ciab444","volume":"73","author":"KM Erlandson","year":"2021","unstructured":"Erlandson KM, Carter CC, Melbourne K, Brown TT, Cohen C, Das M, et al. Weight change following antiretroviral therapy switch in people with viral suppression: pooled data from randomized clinical trials. Clin Infect Dis. 2021;73(8):1440\u201351.","journal-title":"Clin Infect Dis"},{"key":"604_CR29","unstructured":"Haggins D, Mussini C, Zhang F, Kumar PN, Hocqueloux L, Espinosa N, et al. Week 48 metabolic health after switch to DTG\/3TC vs CAR by baseline regimen (SALSA). Presented at: Conference on Retroviruses and Opportunistic Infections; February 12\u201316, 2022; Virtual."},{"issue":"1","key":"604_CR30","doi-asserted-by":"publisher","first-page":"10165","DOI":"10.1038\/s41598-021-89442-7","volume":"11","author":"T Waas","year":"2021","unstructured":"Waas T, Schulz A, Lotz J, Rossmann H, Pfeiffer N, Beutel ME, et al. Distribution of estimated glomerular filtration rate and determinants of its age dependent loss in a German population-based study. Sci Rep. 2021;11(1):10165.","journal-title":"Sci Rep"}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-024-00604-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12981-024-00604-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-024-00604-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T10:09:26Z","timestamp":1711015766000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/s12981-024-00604-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,21]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["604"],"URL":"https:\/\/doi.org\/10.1186\/s12981-024-00604-9","relation":{},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,21]]},"assertion":[{"value":"13 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Both studies were conducted in accordance with the International Conference on Harmonization Good Clinical Practice and followed the principles of the Declaration of Helsinki; all participants provided written informed consent before study initiation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SW has received investigator-initiated grants from Gilead Sciences, Merck, and ViiV Healthcare and has participated in advisory boards for Merck and ViiV Healthcare. DES has served as a consultant for Gilead Sciences and ViiV Healthcare. MG has received grants from Janssen and ViiV Healthcare and consulting fees and honoraria from Janssen, Gilead Sciences, and ViiV Healthcare. PEC has received consulting fees from Gilead Sciences, MSD, and ViiV Healthcare and honoraria from Gilead Sciences and ViiV Healthcare, and has participated in data safety monitoring or advisory boards for Moderna. TL has received funding from GSK, paid to his institution, and grants from Charit\u00e9 Berlin, DAGN\u00c4 e.V., Gilead Sciences, Heidelberg ImmunoTherapeutics GmbH, Leberstiftungs-GmbH, Moderna, and MSD, paid to his institution. KL has received honoraria and travel support from Gilead Sciences, MSD, and ViiV Healthcare. PNK has received grants from Gilead Sciences, GSK, Merck, TheraTechnologies, and ViiV Healthcare, paid to her institution; has received consulting fees from Gilead Sciences, GSK, Merck, and ViiV Healthcare; has participated in data safety monitoring or advisory boards for Gilead Sciences, GSK, Merck, and ViiV Healthcare; and holds stock or stock options in Gilead Sciences, GSK, Johnson & Johnson, Merck, Moderna, and Pfizer. BW, RG, GB, RM, CO, MK, BJ, AC, and MA-K are employees of ViiV Healthcare or GSK and may own stock in GSK.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17"}}